BACKGROUND: Intrathecal morphine forms granulomas that arise from the adjacent arachnoid membrane. The authors propose that these inflammatory cells exit the meningeal vasculature secondary to meningeal mast cell degranulation. METHODS: Three sets of experiments were accomplished in dogs: (1) ex vivo meningeal mast cell degranulation (histamine release was measured ex vivo from canine dura incubated with opiates); (2) in vivo cutaneous mast cell degranulation (flare areas on the dog abdomen were measured after subcutaneous opiates); and (3) in vivo granuloma pharmacology. Dogs with lumbar intrathecal catheters received infusion of intrathecal saline or intrathecal morphine. Intrathecal morphine dogs received (1) no other treatment (control); (2) twice-daily subcutaneous naltrexone; (3) intrathecal co-infusion of cromolyn; or (4) twice-daily subcutaneous cromolyn for the 24- to 28-day study course. RESULTS: Morphine but not fentanyl evoked dural histamine release, which was blocked by cromolyn but not naloxone. Wheal/flare was produced by subcutaneous morphine, methadone, hydromorphone, but not fentanyl, and was unaffected by naltrexone but prevented by cromolyn. Granulomas occurred in all dogs receiving intrathecal morphine (15 of 15); subcutaneous naltrexone had no effect on granulomas (six of six) but was reduced by concurrent intrathecal cromolyn (zero of five) or twice-daily subcutaneous cromolyn (one of five). CONCLUSIONS: The pharmacology of cutaneous/dural mast cell degranulation and intrathecal granulomas are comparable, not mediated by opioid receptors, and reduced by agents preventing mast cell degranulation. If an agent produces cutaneous mast cell degranulation at concentrations produced by intrathecal delivery, the agent may initiate granulomas.
BACKGROUND: Intrathecal morphine forms granulomas that arise from the adjacent arachnoid membrane. The authors propose that these inflammatory cells exit the meningeal vasculature secondary to meningeal mast cell degranulation. METHODS: Three sets of experiments were accomplished in dogs: (1) ex vivo meningeal mast cell degranulation (histamine release was measured ex vivo from canine dura incubated with opiates); (2) in vivo cutaneous mast cell degranulation (flare areas on the dog abdomen were measured after subcutaneous opiates); and (3) in vivo granuloma pharmacology. Dogs with lumbar intrathecal catheters received infusion of intrathecal saline or intrathecal morphine. Intrathecal morphinedogs received (1) no other treatment (control); (2) twice-daily subcutaneous naltrexone; (3) intrathecal co-infusion of cromolyn; or (4) twice-daily subcutaneous cromolyn for the 24- to 28-day study course. RESULTS:Morphine but not fentanyl evoked dural histamine release, which was blocked by cromolyn but not naloxone. Wheal/flare was produced by subcutaneous morphine, methadone, hydromorphone, but not fentanyl, and was unaffected by naltrexone but prevented by cromolyn. Granulomas occurred in all dogs receiving intrathecal morphine (15 of 15); subcutaneous naltrexone had no effect on granulomas (six of six) but was reduced by concurrent intrathecal cromolyn (zero of five) or twice-daily subcutaneous cromolyn (one of five). CONCLUSIONS: The pharmacology of cutaneous/dural mast cell degranulation and intrathecal granulomas are comparable, not mediated by opioid receptors, and reduced by agents preventing mast cell degranulation. If an agent produces cutaneous mast cell degranulation at concentrations produced by intrathecal delivery, the agent may initiate granulomas.
Authors: James A Blunk; Martin Schmelz; Susanne Zeck; Per Skov; Rudolf Likar; Wolfgang Koppert Journal: Anesth Analg Date: 2004-02 Impact factor: 5.108
Authors: Mark R Hutchinson; Yingning Zhang; Mitesh Shridhar; John H Evans; Madison M Buchanan; Tina X Zhao; Peter F Slivka; Benjamen D Coats; Niloofar Rezvani; Julie Wieseler; Travis S Hughes; Kyle E Landgraf; Stefanie Chan; Stephanie Fong; Simon Phipps; Joseph J Falke; Leslie A Leinwand; Steven F Maier; Hang Yin; Kenner C Rice; Linda R Watkins Journal: Brain Behav Immun Date: 2009-08-11 Impact factor: 7.217
Authors: Kirsten Wegner; Kjersti A Horais; Nicolle A Tozier; Michael L Rathbun; Yuri Shtaerman; Tony L Yaksh Journal: J Neurosci Methods Date: 2007-09-29 Impact factor: 2.390
Authors: Tony L Yaksh; Kelly A Eddinger; Shinichi Kokubu; Zhenping Wang; Anna DiNardo; Roshni Ramachandran; Yuelian Zhu; Yajun He; Fieke Weren; Daphne Quang; Shelle A Malkmus; Katherine Lansu; Wesley K Kroeze; Brian Eliceiri; Joanne J Steinauer; Peter W Schiller; Peter Gmeiner; Linda M Page; Keith R Hildebrand Journal: Anesthesiology Date: 2019-07 Impact factor: 7.892
Authors: Armaghan Emami; Jeff Tepper; Brian Short; Tony L Yaksh; Alison M Bendele; Thulasi Ramani; Alvaro F Cisternas; Jay H Chang; R Daniel Mellon Journal: Int J Toxicol Date: 2017-12-21 Impact factor: 2.032
Authors: J Pleticha; S A Malkmus; L F Heilmann; S L Veesart; R Rezek; Q Xu; T L Yaksh; A S Beutler Journal: Gene Ther Date: 2014-10-30 Impact factor: 5.250
Authors: Keith R Hildebrand; Linda M Page; Tina M Billstrom; Joanne J Steinauer; Kelly A Eddinger; Shervin Arjomand; Tony L Yaksh Journal: Neuromodulation Date: 2019-05-23
Authors: Shinichi Kokubu; Kelly A Eddinger; Shigeki Yamaguchi; Lena Libertad Huerta-Esquivel; Peter W Schiller; Tony L Yaksh Journal: Neuromodulation Date: 2019-02-22